Elritercept

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameElritercept
Drug Alias NameKER-050HS-20106HS20106TAK-226
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionAnti-TGF-β
TargetsTransforming growth factor beta
Therapy Area/IndicationsCytopeniaPrimary MyelofibrosisMyelodysplastic Syndromes +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKeros Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKeros Therapeutics IncHansoh Pharmaceutical Group Company LtdTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCytopeniaPrimary MyelofibrosisMyelodysplastic Syndromes +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG